The new drug was sanctioned based on the Phase 3 MAESTRO-NASH trial results, which showcased significant improvement in patients after 52 weeks of treatment at both 100mg and 80mg doses.

The authors recommend that large controlled trials of extended duration should be performed to establish the long-term safety and efficacy of pioglitazone as a treatment for NASH.

Historically, the absence of FDA-approved treatments specifically targeting NASH has left many patients and healthcare providers with limited options, often focusing on lifestyle changes with ...

adding that the child would likely need stitches. Authorities took the dog, which was confined inside a car when they arrived, to Nash County Animal Services and went to the owner’s home in ...